Obalon Therapeutics, Inc. (OBLN) financial statements (2021 and earlier)

Company profile

Business Address 5421 AVENIDA ENCINAS
SAN DIEGO, CA 92008
State of Incorp. DE
Fiscal Year End December 31
SIC 3841 - Surgical and Medical Instruments and Apparatus (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in millions)

12/31/2020
12/31/2019
12/31/2018
12/31/2017
12/31/2016
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments414244475
Cash and cash equivalents414212173
Short-term investments  3233
Receivables30141
Inventory, net of allowances, customer advances and progress billings 2211
Inventory 2211
Other current assets42221
Other undisclosed current assets(3)    
Total current assets:818295278
Noncurrent Assets
Operating lease, right-of-use asset11
Property, plant and equipment11211
Other undisclosed noncurrent assets1    
Total noncurrent assets:32211
TOTAL ASSETS:1120305379
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities, including:11561
Accounts payable1111 
Accrued liabilities    1
Employee-related liabilities01442
Interest and dividends payable    0
Other undisclosed accounts payable and accrued liabilities    (3)
Deferred revenue 0
Debt 1102 
Deferred revenue and credits1 
Other liabilities42221
Other undisclosed current liabilities1 0 3
Total current liabilities:5417105
Noncurrent Liabilities
Long-term debt and lease obligation11 810
Long-term debt, excluding current maturities0  810
Operating lease, liability01
Liabilities, other than long-term debt0 00 
Deferred revenue and credits0 
Deferred rent credit  0
Other liabilities0    
Total noncurrent liabilities:110810
Total liabilities:65171814
Stockholders' equity
Stockholders' equity attributable to parent516133564
Common stock00000
Additional paid in capital189188162146141
Accumulated other comprehensive loss   (0)(0)
Accumulated deficit(185)(172)(149)(111)(77)
Total stockholders' equity:516133564
TOTAL LIABILITIES AND EQUITY:1120305379

Income statement (P&L) ($ in millions)

12/31/2020
12/31/2019
12/31/2018
12/31/2017
12/31/2016
Revenues239103
Revenue, net103
Cost of revenue(1)(3)(5)(5)(3)
Cost of goods and services sold(1)    
Gross profit:10451
Operating expenses(13)(24)(41)(39)(20)
Operating loss:(12)(23)(37)(34)(20)
Nonoperating expense
(Other Nonoperating expense)
(0)(0)(0)(0)(0)
Net loss:(12)(23)(37)(35)(20)
Other undisclosed net income (loss) attributable to parent0(0)(0)(0)(1)
Net loss available to common stockholders, diluted:(12)(24)(37)(35)(20)

Comprehensive Income ($ in millions)

12/31/2020
12/31/2019
12/31/2018
12/31/2017
12/31/2016
Net loss:(12)(23)(37)(35)(20)
Other comprehensive income (loss)  0(0)(0)
Comprehensive loss:(12)(23)(37)(35)(20)
Other undisclosed comprehensive income (loss), net of tax, attributable to parent0(0)(0)(0)(1)
Comprehensive loss, net of tax, attributable to parent:(12)(24)(37)(35)(20)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: